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A B S T R A C T
Purpose: To review our clinical experience and determine if there are appropriate signs and symptoms to
consider POLG sequencing prior to valproic acid (VPA) dosing in patients with seizures.
Methods: Four patients who developed VPA-induced hepatotoxicity were examined for POLG sequence
variations. A subsequent chart review was used to describe clinical course prior to and after VPA dosing.
Results: Four patients of multiple different ethnicities, age 3–18 years, developed VPA-induced
hepatotoxicity. All were given VPA due to intractable partial seizures. Three of the patients had
developed epilepsia partialis continua. The time from VPA exposure to liver failure was between 2 and 3
months. Liver failure was reversible in one patient. Molecular studies revealed homozygous p.R597W or
p.A467T mutations in two patients. The other two patients showed compound heterozygous mutations,
p.A467T/p.Q68X and p.L83P/p.G888S. Clinical ﬁndings and POLG mutations were diagnostic of Alpers–
Huttenlocher syndrome.
Conclusion: Our cases underscore several important ﬁndings: POLG mutations have been observed in
every ethnic group studied to date; early predominance of epileptiform discharges over the occipital
region is common in POLG-induced epilepsy; the EEG and MRI ﬁndings varying between patients and
stages of the disease; and VPA dosing at any stage of Alpers–Huttenlocher syndrome can precipitate liver
failure. Our data support an emerging proposal that POLG gene testing should be considered in any child
or adolescent who presents or develops intractable seizures with or without status epilepticus or
epilepsia partialis continua, particularly when there is a history of psychomotor regression.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
journal homepage: www.e lsev ier .com/ locate /yse iz1. Introduction
Alpers1 described the syndrome that bears his name; refractory
seizures, developmental regression, cortical blindness, and age of
onset 3–7 years. The liver ﬁndings were subsequently noted byAbbreviations: POLG, polymerase gamma; VPA, valproic acid; MELAS, mitochon-
drial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; MERRF,
myoclonus, epilepsy with ragged red ﬁbers; MRI, magnetic resonance imaging;
MRS, proton (1H) magnetic resonance spectroscopy; FLAIR, ﬂuid attenuated
inversion recovery; MPV17, mitochondrial inner membrane protein; TWINKLE,
gene encoding mitochondrial helicase; PCR, polymerase chain reaction.
* Corresponding author. Tel.: +1 713 798 1940; fax: +1 713 798 8937.
E-mail address: ljwong@bcm.edu (L.C. Wong).
1 These authors contributed equally.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.01.002Huttenlocher et al.2 However, it was not until Bicknese et al.3
described valproic acid (VPA) toxicity in six children with
Huttenlocher variant of Alpers syndrome that VPA-induced liver
toxicity and Alpers syndrome were connected [Alpers–Huttenlo-
cher syndrome is synonymous with Alpers syndrome]. Subse-
quently, Naviaux and Nguyen4 made the discovery that mutations
within the mitochondrial DNA replicase, polymerase gamma 1
(POLG) was responsible for Alpers–Huttenlocher syndrome.
Although now, POLG mutations, Alpers–Huttenlocher syndrome,
and VPA-induced liver failure are known, there remains the
question on how to predict patient populations where VPA
exposure should be avoided.
The mechanism of POLG with VPA-induced liver failure is not
clear. POLG together with deoxyguanosine kinase and MPV17, are
the nuclear genes responsible for most cases of the hepatocerebralvier Ltd. All rights reserved.
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Only the mutations in POLG and the mitochondrial DNA helicase
TWINKLE have been associated with genetically proven VPA-
induced liver failure.8 Human POLG is a heterotrimer, composed of
one p140 catalytic subunit encoded by the POLG gene and two p55
accessory subunits encoded by the POLG2 gene.9,10 More than 150
pathogenic POLG mutations have been reported in patients with a
broad spectrum of clinical phenotypes (http://tools.niehs.nih.gov/
polg/).
In this study, we describe the ﬁnding of four cases including
infant, child, adolescent, and young adult from different ethnic
backgrounds who developed liver failure in response to VPA
dosing. Regardless of the age of onset of seizures, administration of
VPA precipitated liver failure within 2–3 months. Due to our
increased understanding of this syndrome, we tested two other
children for possible POLGmutations prior to exposure to VPA and
they are still alive.
2. Methods
2.1. Patients and DNA
Blood samples of patientswith clinical presentations suggestive
of POLG deﬁciency were evaluated at the Mitochondrial Diag-
nostics Laboratory at Baylor College ofMedicine. Total (nuclear and
mitochondrial) DNA was extracted from peripheral blood leuko-
cytes using commercially available DNA isolation kits (Gentra
Systems Inc., Minneapolis, MN), according to the manufacturer’s
protocols.Table 1
Summary of clinical course of patients exposed to VPA.
Patient
1 2
Gender/age (years) Male/18 Female/2
Genotype allele 1/allele 2 c.1789C>T/c.1789C>T c.1399G
Amino acid change p.R597W/p.R597W p.A467T
Ethnicity Hispanic Caucasia
Health status before seizure onset Normal developmental and growth
status; pulmonary tuberculosis at
14-years and recovery
Sensory
ataxia si
MRI of brain (hyperintensity
on T2/FLAIR sequences)
Left cerebellar hemisphere, right
cerebellar vermis, left thalamus,
left centrum semiovale
(1) Right
left thala
right occ
(2) Norm
Age of seizure onset (year) 14 15
Seizure type CPS SPS and
EEG Generalized Right oc
EEG, bac
Drug for seizure control OXC, PHT, VPA LTG stab
Duration (month) of add-on VPA
before hepatotoxicity
2 months 3 month
Course after hepatotoxicity Liver failure, renal failure
and pancreatitis
Liver tra
progress
Lactate 30mmol/L (normal 0.5–1.7mmol/L) ND
Other phenotype Ophthalmoplegia, peripheral
neuropathy
Sensorin
dysmetr
hypoton
Outcome Expired at 18.5 years Expired
SPS, simple partial seizure; CPS, complex partial seizure; EPC, epilepsia partialis continua
posterior cerebral artery; CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; V
phenobarbital; PLEDs, periodic lateralized epileptiform discharges.2.2. Sequencing analysis
Sequence-speciﬁc oligonucleotide primers linked to M13
universal primer sequences were designed to amplify the 22
coding exons and at least 50 nucleotides of each ﬂanking intron of
POLG gene. PCR products generated using Fast Start DNA
polymerase (Roche, Indianapolis, IN) were puriﬁed on ExcelaPure
96-well UF PCR puriﬁcation plates (Edge BioSystems, Gaithersburg,
MD). Sequencing reactions were performed using the BigDye
Terminator Cycle Sequencing kit (Version 3.1) and analyzed on an
ABI3730XL automated DNA sequencer with Sequencing Analysis
Software v5.1.1 (Applied Biosystems, Foster City, CA, USA). DNA
sequences were analyzed using Mutation Surveyor Version 2.6.1
and the GenBank POLG sequence; ID NM_002693.1.
2.3. Clinical reports
2.3.1. Patient 1
This patient is an 18-year-old Hispanic male, who displayed
normal development until 14 years of age when he was diagnosed
with pulmonary tuberculosis (Table 1). He had a full recovery. His
ﬁrst seizures were complex partial seizures also occurred at 14
years of age. He failed antiepileptic therapy with oxcarbazepine
and he was placed on VPA. In 2 months, he had bilateral foot drop,
pes cavus, and mild ophthalmoplegia without obvious cognitive
abnormality. Electromyography (EMG) testing demonstrated a
peripheral neuropathy.Within 24 h ofmuscle biopsy he developed
pancreatitis that progressed to multiple organ failure including
kidneys, liver, lung, and pancreas. VPA was stopped. The muscle3 4
3 Female/3.3 Female/10
>A/c.1399G>A c.1399G>A/c.202C>T c.T248C/c.G2662A
/p.A467T p.A467T/p.Q68X p.L83P/p.G888S
n Caucasian Chinese
neuropathy,
nce 10 years
Celiac disease,
mild developmental
delay, ataxia
Mild elevation of hearing
threshold at age 5-years
and left frontal lobe,
mus, bilateral parietal,
ipital
al
Left cerebellum Semiovale, cerebellum
periventricular white
matter, right occipital
2.8 9
EPC myoclonus CPS, EPC, visual
hallucination,
and myoclonus
CPS, EPC, status
epilepticus
cipital spikes, normal
kground slow, PLEDs
Left occipital spikes/right
occipital spikes (varied
with EEG), background
slow
Background slow, left
central and parietal
spikes, left hemisphere
periodic discharges,
bilateral occipital spikes
le for 7 years, VPA OXC, VPA PHT, CBZ, VPA, LTG,
TOP, CLON
s 3 months 2.5 months
nsplantation,
ive encephalopathy
Encephalopathy Psychomotor regression,
vegetative state
Normal Normal
eural hearing loss,
ia, intention tremor,
ia
Chronic constipation,
cyclic vomiting,
hypotonia, absent
smooth pursuit
Leukodystrophy,
right PCA infarct in MRI,
cortical blindness at
9.5 years
at 23.5 years Expired at 3
years 4 months
Survived
; MRI, magnetic resonance imaging; FLAIR, ﬂuid attenuated inversion recovery; PCA,
PA, valproic acid; LTG, Lamotrigine; CLON, clonazepam; TOP, topiramate; and PB,
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negative ﬁbers. Electron microscopy showed abnormal mitochon-
drial ultrastructure with increased lipid droplets. Although VPA
was stopped, his liver function impairment progressed. Despite
aggressive supportive care, he unfortunately died of sepsis and
adult respiratory distress syndrome 27 days after the biopsy.
2.3.2. Patient 2
POLG mutations and brief symptoms list have been brieﬂy
described.11 Previously healthy until 10-years of age the patient
developed drop attacks suggestive of ataxia ormyoclonic seizures
with electroencephalogram (EEG) showed photic convulsive
responses and infrequent generalized discharges during slow
wave sleep (Table 1). She was found to have a mild sensorineural
hearing loss. At 15 years of age, she developed epilepsia partialis
continua (EPC). EEG demonstrated right occipital epileptiform
discharges. EMG examination demonstrated amoderate to severe
symmetric sensory and motor axonal peripheral neuropathy of
lower extremities. A brainMRI showedmultiple hyperintense T2/
FLAIR (ﬂuid attenuated inversion recovery) changes in the right
inferior frontal lobe, left medial frontal lobe, left thalamus,
bilateral parietal, and occipital lobes with the most prominent
lesion being the right occipital lobe. Repeated MRI 1 month later
showed resolution of these changes. Muscle biopsy showed ﬁber
type 2 predominance (60%), and scattered COX-negative ﬁbers
(6%). Electron transport chain (ETC) enzyme testing showed<15%
of normal activity in complex III. Muscle and lymphocyte mtDNA
was negative for common mitochondrial DNA mutations.
Lamotrigine was started and she became seizure free and EEG
normalized. She did extremely well clinically until age 21, when
she developed increasing bouts of myoclonus. Initially, the
myoclonus responded to levetiracetam but after several months
myoclonus became more severe and VPA was added. Within 2
months she developed cognitive slowing, VPA was stopped, and
she was hospitalized for increasing encephalopathy and myoclo-
nus. At admission, she was found to be in liver failure. EEG
demonstrated generalized slowing without epileptiform dis-
charges. MRI of the brain was normal. One month after VPA was
stopped, liver transplant was performed. Following transplant
her liver function normalized but she developed periodic
lateralized epileptiform discharges on EEG. Mechanical ventila-
tion could not be weaned due to pulmonary edema and a right
pneumothorax. Life support was withdrawn. She died within 2
days of transplant. Liver biopsy of her pre-transplanted liver
showed extensive necrosis, bile stasis, bile ductular proliferation,
moderate lymphoplasmacytic inﬁltration, and bridging ﬁbrosis
on Masson trichrome stain. The transplanted liver was normal at
autopsy.
2.3.3. Patient 3
The patient was initially brought to medical attention due to
frequent vomiting (projectile) episodes beginning during infancy.
POLG mutations and brief symptom summary have been previ-
ously reported.11 The mother had Crohn’s disease and the father’s
family had multiple members with Celiac and thyroid disease
(autoimmune). At 18months of age, she developedmyoclonic jerks
and was noted to be mildly ataxic with developmental delay
(Table 1). An EEG was performed and demonstrated occipital
epileptiform discharges. Due to formula intolerance and family
history, at 33 months of age she was evaluated for possible Celiac
disease. She had elevated endomysial IgA and transglutamase IgA
titers and persistent eosinophilia. On small bowel biopsy, she
showed features consistent with but not diagnostic of Celiac
disease. MRI scan showed two foci of hyperintense T2/FLAIR
lesions in the medial aspect of the left cerebellar hemisphere. MRI
gradient echo sequences did not detect calciﬁcations. A gluten freediet had no effect on formula tolerance, seizures or ataxia.
Subsequently, she developed EPCwith left hand clonicmovements
and eye deviation to the left with visual hallucination of seeing
spiders. EPC was effectively treated with lorazepam, fosphenytoin,
and phenobarbital. She developed myoclonus. The EEG during this
time continued to show occipital epileptiform discharges (Fig. 1a
and b). The posterior dominant rhythm was slow. Seizures
continued, and VPA was started at age 3 years. Due to increasing
obtundation and seizures, she was admitted to the hospital 3
months after starting VPA. On admission, liver failure was noted.
VPA was stopped. MRI was repeated showing increased T2/FLAIR
signal in the periventricular white matter, bilateral caudate, and
thalami. The previous cerebellar lesions had resolved. The child’s
parents decided to take her home on hospice and she expired
within 3 weeks.
2.3.4. Patient 4
This 10-year-old Chinese girl had unremarkable growth and
development except a mild elevation of hearing threshold,
detected at 5 years of age. This patient has been previously
described.12 Brieﬂy, seizures started at 9 years of age and were
multifocal partial seizures that often progressed to status
epilepticus. EEG showed frequent epileptiform discharges over
central, parietal, and occipital regions with slowing of the
background (Table 1). Repeated EEG 7 months later demonstrated
generalized slowing, periodic slow and spike wave over the left
hemisphere, and almost continuous spike and wave discharges
over the bi-occipital regions. Due to intractability to multiple
medications, VPA was started. VPA was stopped after 2.5 months
due to liver failure. Since the initial report,12 her liver function
gradually improved and now has returned to near normal
functioning. Clinically, she has demonstrated development regres-
sion, losing the ability to walk, sit, or speak and eventually
progressed to a vegetative state. She remained in a vegetative state
until death at age 13.
2.3.5. Patient 5
Patient 5 (Table 2) did not receive VPA and will be discussed
later. The 11-year-old boy was normal developing until 2.5 years,
when he developed gait ataxia with repeated episodes of ketotic
hypoglycemia in the context of cyclic vomiting, requiring multiple
hospitalizations. He developed seizures at 6-years of age and
seizures have been intractable to antiseizure medications. An EEG
at 10 years of age demonstrated generalized epileptiform
discharges suggesting generalized epilepsy (Fig. 2). Muscle biopsy
was performed for a suspicion of mitochondrial disease. ETC
results were normal and histochemical studies of the muscle
demonstrated scattered COX-negative ﬁbers. POLG sequencing
demonstrated compound heterozygous mutations, p.A467T and
p.G848S. Currently at 11-years of age, he has severe gastro-
intenstinal dysmotility, intractable generalized seizures, ophthal-
moplegia, myoclonus, bilateral eyelid ptosis, axial hypotonia,
muscle weakness and fatigue, and cognitive regression. He has just
begun to develop signs and symptoms of liver failure.
2.3.6. Patient 6
Patient6 (Table 2) didnot receiveVPAandwill bediscussed later.
The 4-year-old girl began having seizures at the age of 2 years, with
EPC arising from the right occipital head region. The seizures were
described as eye jerking/nystagmus to the left and right. Seizures
were treated with levetiracetam and oxcarbazepine. She became
seizure free after several days of combination therapy, However,
there remained frequent spike and wave discharges in the right
occipital region on EEG. Otherwise her development has been on
tract. On neurological examination there is a mild wide-based gait
with truncal ataxia. She also has an intention tremor. TheMRI of the
Fig. 1. This EEG epoch demonstrates occipital lobe epileptiform discharges of patient 3 at age 3 years. (a) Bipolar montage and predominant right occipital discharges. (b)
Same epoch but in a transverse montage. This view shows that the predominant discharge is right occipital. The background rhythm is slow for age. Interestingly, in other
EEGs, the occipital discharge was predominantly left occipital.
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Table 2
Summary of clinical course of patients not exposed to VPA.u.
Patient
5 6
Gender/age (years) Male/11 Female/2
Genotype allele 1/allele 2 c.1399G>A/c.2542G>A c.2542G>A/c.2243G>C
Amino acid change A467T/G848S G848S/W748S
Ethnicity Caucasian Caucasian
Health status before seizure onset Cyclic vomiting, episodic hypoglycemia Normal
MRI of brain (hyperintensity on T2/FLAIR sequences) Normal Normal
Age of seizure onset (years) 6 4
Seizure type Generalized CPS, EPC
EEG Generalized spikes, background slow Right occipital
Drug for seizure control CBZ, OXC, LTG, ZNS, LEV, TPM LEV, OXC
Duration (month) of add-on VPA before hepatotoxicity VPA not given VPA not given
Course after hepatotoxicity N/A N/A
Lactate Normal Normal
Other phenotype GI dysmotility, eyelid ptosis,ophthalmoplegia,
sensorineural hearning loss, absent smooth
pursuit eye movements
Truncal ataxia, intention tremor
Outcome Alive Alive
EEG, encephalogram; MRI, magnetic resonance imaging; FLAIR, ﬂuid attenuated inversion recovery; GI, gastrointestinal; CPS, complex partial seizure; GTC, general tonic
seizure; SE, status epilepticus; VPA, valproic acid; CBZ, carbamazepine; PHT, phenytoin; OXC, oxcarbazepine; LTG, Lamotrigine; CLON, clonazepam; TPM, topiramate; LEV,
levetiracetam; GAB, gabapentin; and FOS, fosphenytoin.
Fig. 2. This EEG epoch shows generalized epileptiform discharges in a bipolarmontage (patient 5). This epoch demonstrates a large amplitude spike andwave discharge (large
delta discharge followed by a notched spike) at 2–2.5 Hz. There is also an intermittent slow that is maximal bi-occipital with left occipital predominance. The background
rhythm is slow for age.
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tions p.G848S and p.W748S mutations.
3. Results
Only one (patient 2) of the four patients (with liver failure)
described above was suspected of having a mitochondrial disorder
at the time of VPA dosing. She had a deﬁciency of complex III notedon electron transport chain analysis. All patients were on
polytherapy for seizure control. The entire mitochondrial genome
of patient 1 was sequenced but deleterious mutations were not
found. None of the patients were thought to have Alpers–
Huttenlocher syndrome. The sentinel ﬁnding of VPA-induced liver
failure triggered mutational analysis of POLG in patients 1–4.
Gene sequencing revealed a missense variant, c.1789C>T
(p.R597W), in patient 1. In patient 2, a common homozygous
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compound heterozygous for a missense mutation, c.1399G>A
(p.A467T) and a nonsense mutation, c.202C>T (p.Q68X). Patient 4
was compound heterozygous for two missense variants, c.248T>C
(p.L83P) and c.2662G>A (p.G888S).
All patients had conﬁrmed pathogenic mutations in POLG gene.
Our four patients are of diverse ethnic background and the age of
disease onset varies from infants to adolescents to young adults.
Early growth and development appeared normal until the ﬁrst
seizures at 9 and 14 years of age for patients 4 and 1. Patient 2 had
early ataxia with myoclonus and mild sensorineural hearing loss.
Myoclonuswas essentiallywell controlledwith lamotrigine. At 22-
years of age, VPA was started. Although she was found to have a
complex III defect, she was homogygous for the p. A467Tmutation
and at autopsy had pathological ﬁndings of liver and brain (data
not presented) consistent with Alpers–Huttenlocher syndrome.
Complex IV defects have been found in Alpers–Huttenlocher
patients13 and our patient 2 would suggest that complex III defects
are also compatible with Alpers–Huttenlocher syndrome. Patient 3
presented in infancy with projectile vomiting. Each patient
developed intractable complex partial seizures, with 3 patients
developing EPC and/or status epilepticus. In all patients VPA was
administered for seizure control, ultimately leading to liver failure
and a genetic diagnosis. The time to liver failure was short in each,
approximately 3 months after VPA exposure. Patient 2 underwent
an unsuccessful liver transplant. Patients 1–3 died of acute
problems from liver failure or transplant, while patient 4
eventually died from complications of liver failure.
4. Discussion
The incidence of fatal VPA-induced hepatotoxicity decreases
with increasing age. In adults, the incidence is about 1:40,000.14 In
children under 2 years receiving polytherapy of VPA with other
antiepileptic medications, liver toxicity can be as high as 1/600.14
VPA is the medication of choice for generalized seizure15,16 and
efﬁcacious in focal seizures as noted in many studies and expert
opinion articles.17–19 The efﬁcacy of VPA in controlling both
generalized and focal seizures in the context of VPA-induced
hepatic failure makes clinical acumen of its use extremely
important. Thinking that VPA-induced liver failure is an age-
related disorder, many clinicians do not hesitate to use VPA in
patients >2 years with uncontrolled seizures. Furthermore, VPA is
the medication of choice in another mitochondrial disease
syndrome, myoclonus, epilepsy with ragged red ﬁbers (MERRF).20
Our data, together with the broad age range of patients with
reported VPA-induced liver failure with POLG mutations, suggests
that VPA exposure is related to POLG genotype and disease, in
particular Alpers–Huttenocher syndrome.21–27
The onset of seizures may give clues to the presence of POLG
mutations and Alpers–Huttenlocher syndrome. Several reports
have shown that patients with POLG mutations and Alpers–
Huttenlocher syndrome present with syndromic epilepsy with
occipital lobe predilection.5,21,23–25 In addition, our patient
population (Table 1) and recent literature demonstrates seizure
semiology consistent with occipital lobe epileptic discharges; focal
clonic motor seizures, secondarily generalized tonic–clonic sei-
zures, hallucinations and nystagmus.23–25,28 However, early
studies have not consistently shown occipital lobe discharges,
with some describing generalized discharges, hypsarrhythmia or
multifocal discharges.28,29 Tulinius and Hagne28 suggested that
timing of the disease progression was likely responsible for EEG
variation. The predominance of reports with POLG proven Alpers–
Huttenlocher syndrome strongly suggests that the majority of
patients presenting with seizures have predominantly occipital
lobe discharges. Often discharges are seen in the context of EPC orstatus epilepticus.23–25 In one small study, ﬁve patients presented
with convulsive status epilepticus.21 Three of four of our patients
would compliment focal EEG ﬁndings within the occipital region
and EPC in the course of their disease. However, not all patients
having Alpers–Huttenlocker have focal EEG patterns. Patients 2
and 5 had generalized spikes, more reminisce of the report by Boyd
et al.29 One of our patients (patient 2) demonstrated that normal
EEG ﬁndings are also possible during the course of the syndrome.
We agree with Tulinius and Hagne28 that EEG may change during
the course of this disorder. Most patients, at the time of seizure
onset will display a focal pattern with posterior head distribution.
Some may have generalized discharges, but this is likely
uncommon early, but may be seen later in the course of the
disorder (patients 2 and 5). As demonstrated in our patients, most,
if not all, will have abnormal slowing of the background frequency
suggesting encephalopathy. However, the EEGmay also be normal
as seen in patient 2.
In one study, epileptiformdischargeswere high amplitude delta
frequency waves with superimposed polyspikes.21 However, this
was not the case in our population (Figs. 1 and 2). This would
suggest that although the EEG is very helpful in location and
frequency of epileptiform discharges, discharges can be variable
and clinical acumen is required interpreting ﬁndings with
diagnostic conclusions.
Three of our patients (patients 2–4) had EPC sometime in their
disease, with another patient (patient 4) having a status epilepticus
event. Patient 1 did not have documented episodes of either EPC or
status epilepticus. The literature and our ﬁndings would suggest
that most patients with Alpers–Huttenlocher syndrome have
explosive seizure onset, usually presenting with occipital lobe
semiologies and frequent bouts of EPC and/or status epilepticus
during the course of their disease. Patients with other mitochon-
drial diseases such as Leigh syndrome, MELAS, mitochondrial
transfer RNA mutations and electron transport chain disorders
have been associated with EPC.30–32 Therefore, careful evaluations
for other possible mitochondrial diseases33–35 and other etiologies
of EPC need to be investigated.
Most of the other patients with POLG mutations and VPA-
induced liver toxicity were reported from Caucasian of Northern
European countries and had similar POLG mutations.23–25 Our
patients are of diverse ethnicities including Hispanic, Caucasian,
northern European, and Chinese. This emphasizes that POLG
mutations andVPAhepatotoxicity can be pan-ethnic. Furthermore,
VPA-induced hepatotoxicity can happen at any age or stage of the
disorder.
Screening of the ﬁve most common mutations, p.A467T,
p.W748S, p.G848S, p.T914P, and p.T251I + p.P587L in POLG gene
would detect both mutant alleles in about half of cases with
recessive POLG-related disease and one mutant allele in about one
third of cases.11 However, our experience and the literature22,36
suggests that other mutations exist and therefore, screening for
these most frequent mutations may not adequately screen for
POLG-related disorder in a particular patient. Therefore, full gene
sequencing of POLG is currently themost efﬁcaciousmethod to use
before VPA dosing.
Review of the cases with POLG mutations and liver failure
induced by VPA revealed that most patients had unremarkable
clinical history before seizure onset. Often the early clues to a
particular mitochondrial DNA depletion syndrome are elusive and
therefore, more caution is required. Any ethnicity should be
suspected. Early development is likely to be normal. The initial
symptoms may be explosive seizures that have an occipital lobe
predominance and difﬁcult to control with medications. Seizures
may occur at any age during infancy through adolescence. The EEG
patternwill often be focal discharges from the occipital lobe region
and seizure semiology will be compatible with occipital lobe
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epilepticus. If there are MRI/MRS abnormalities present, they will
likely be represented by T2/FLAIR hyperintensity signalswithin the
thalamus, occipital region, and/or cerebellum (Table 1).21,28 MRS
imaging may show the presence of lactate peaks.21,33 Progressive
psychomotor regression is almost universally found when ﬁrst
symptoms appear. In this clinical scenario, POLG gene sequencing
should be performed. Using these principles, we have performed
POLG gene sequencing prior to VPA dosing based on clinical
suspicion (Table 2). Patients 5 and 6 were found to harbor
compound heterozygous mutations described with Alpers–Hut-
tenlocher syndrome. Both patients are currently alive.
Currently, sequencing the POLG gene remains the best
diagnostic test to prevent VPA-induced liver failure and patient
death. Although open to debate, it is our suggestion that POLG gene
testing should be standard before giving VPA for seizure treatment
in this genetic mitochondrial DNA depletion epilepsy syndrome.
Our patients 5 and 6 are alive because our clinical acumen induced
our decision to sequence the POLG gene.
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